Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


06.02.2017

1 Ann Oncol
12 Anticancer Res
1 BMC Cancer
2 BMC Gastroenterol
2 Br J Cancer
1 Cancer
2 Cancer Res
5 J Clin Oncol
1 Oncology
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. AUCLIN E, Zaanan A, Vernerey D, Douard R, et al
    Subgroups and Prognostication in Stage III Colon Cancer: Future Perspectives for Adjuvant Therapy.
    Ann Oncol. 2017 Jan 27. pii: mdx030. doi: 10.1093.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. TRESKA V
    Methods to Increase Future Liver Remnant Volume in Patients with Primarily Unresectable Colorectal Liver Metastases: Current State and Future Perspectives.
    Anticancer Res. 2016;36:2065-71.
    PubMed     Text format     Abstract available

  3. RADIC J, Kruslin B, Samija M, Ulamec M, et al
    Connexin 43 Expression in Primary Colorectal Carcinomas in Patients with Stage III and IV Disease.
    Anticancer Res. 2016;36:2189-96.
    PubMed     Text format     Abstract available

  4. WISNIEWSKI J, Wesolowska O, Sroda-Pomianek K, Paprocka M, et al
    Euphorbia Species-derived Diterpenes and Coumarins as Multidrug Resistance Modulators in Human Colon Carcinoma Cells.
    Anticancer Res. 2016;36:2259-64.
    PubMed     Text format     Abstract available

  5. SADAHIRO S, Suzuki T, Tanaka A, Okada K, et al
    Increase in Gene Expression of TYMP, DPYD and HIF1A Are Associated with Response to Preoperative Chemoradiotherapy Including S-1 or UFT for Rectal Cancer.
    Anticancer Res. 2016;36:2433-40.
    PubMed     Text format     Abstract available

  6. KAWAGUCHI D, Hiroshima Y, Matsuo K, Endo I, et al
    Parenchymal Congestion Is Important for Rapid Regeneration of the Future Liver Remnant Following the ALPPS Procedure.
    Anticancer Res. 2016;36:4731-8.
    PubMed     Text format     Abstract available

  7. SHIN YR, Kim KA, Im S, Hwang SS, et al
    Prediction of KRAS Mutation in Rectal Cancer Using MRI.
    Anticancer Res. 2016;36:4799-804.
    PubMed     Text format     Abstract available

  8. CHIEN CR, Chen WT, Wang HM, Ke TW, et al
    A Comparative Effectiveness Study of Two Oral Chemotherapy Drugs (UFT vs. Capecitabine) in Neoadjuvant Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer.
    Anticancer Res. 2016;36:6155-6160.
    PubMed     Text format     Abstract available

  9. SHANY S, Sigal-Batikoff I, Lamprecht S
    Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-purposes with TGF-beta/SMAD Signaling.
    Anticancer Res. 2016;36:6225-6234.
    PubMed     Text format     Abstract available

  10. YEO MK, Lee YM, Seong IO, Choi SY, et al
    Up-regulation of Cytoplasmic CD24 Expression Is Associated with Malignant Transformation but Favorable Prognosis of Colorectal Adenocarcinoma.
    Anticancer Res. 2016;36:6593-6598.
    PubMed     Text format     Abstract available

  11. MORIS D, Dimitroulis D, Vernadakis S, Papalampros A, et al
    Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes.
    Anticancer Res. 2017;37:9-14.
    PubMed     Text format     Abstract available

  12. RUBIO CA
    Three Pathways of Colonic Carcinogenesis in Rats.
    Anticancer Res. 2017;37:15-20.
    PubMed     Text format     Abstract available

  13. YAMAUCHI K, Kokuryo T, Yokoyama Y, Uehara K, et al
    Prediction of Early Recurrence After Curative Resection of Colorectal Liver Metastasis and Subsequent S-1 Chemotherapy.
    Anticancer Res. 2016;36:2175-9.
    PubMed     Text format     Abstract available


    BMC Cancer

  14. HENRIKSEN HB, Raeder H, Bohn SK, Paur I, et al
    The Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET) study: a food-based multicentre randomized controlled trial.
    BMC Cancer. 2017;17:83.
    PubMed     Text format     Abstract available


    BMC Gastroenterol

  15. SIRIPONGPREEDA B, Mahidol C, Dusitanond N, Sriprayoon T, et al
    High prevalence of advanced colorectal neoplasia in the Thai population: a prospective screening colonoscopy of 1,404 cases.
    BMC Gastroenterol. 2016;16:101.
    PubMed     Text format     Abstract available

  16. BURKE CA, Dekker E, Samadder NJ, Stoffel E, et al
    Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    BMC Gastroenterol. 2016;16:87.
    PubMed     Text format     Abstract available


    Br J Cancer

  17. CARTER JV, Galbraith NJ, Yang D, Burton JF, et al
    Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis.
    Br J Cancer. 2017 Feb 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  18. HU H, Shu M, He L, Yu X, et al
    Epigenomic landscape of 5-hydroxymethylcytosine reveals its transcriptional regulation of lncRNAs in colorectal cancer.
    Br J Cancer. 2017 Jan 31. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    Cancer

  19. YANG B, Gapstur SM, Newton CC, Jacobs EJ, et al
    Alcohol intake and mortality among survivors of colorectal cancer: The Cancer Prevention Study II Nutrition Cohort.
    Cancer. 2017 Jan 30. doi: 10.1002/cncr.30556.
    PubMed     Text format     Abstract available


    Cancer Res

  20. USHIJIMA T, Yoshino T
    The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer.
    Cancer Res. 2016;76:6443-6444.
    PubMed     Text format    

  21. ROKAVEC M, Hermeking H
    Cellular model of colon cancer progression reveals signatures of mRNAs, miRNA, lncRNAs and epigenetic modifications associated with metastasis.
    Cancer Res. 2017 Jan 27. pii: canres.3236.2016.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. YURGELUN MB, Kulke MH, Fuchs CS, Allen BA, et al
    Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
    J Clin Oncol. 2017 Jan 30:JCO2016710012. doi: 10.1200/JCO.2016.71.0012.
    PubMed     Text format     Abstract available

  23. GOUGH K, Drosdowsky A, Russell L, Aranda S, et al
    A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC).
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available

  24. VAN LOON K, You YN, Hu CY, Francescatti AB, et al
    How clinicians make decisions regarding surveillance and treatment of colorectal cancer (CRC) patients.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available

  25. SMITH V, Danus S, Schnell M, Lindquist J, et al
    Colorectal cancer survivorship statistics: A Veterans Affairs Central Cancer Registry analysis.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available

  26. HEGARTY S, Shapiro PJ, Fang CY, Barsevick AM, et al
    Physical and mental functioning in colorectal cancer (CRC) survivors by work status.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


    Oncology

  27. HASEGAWA H, Taniguchi H, Mitani S, Masuishi T, et al
    Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
    Oncology. 2017 Feb 1. doi: 10.1159/000453336.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  28. HSIA LT, Ashley N, Ouaret D, Wang LM, et al
    Myofibroblasts are distinguished from activated skin fibroblasts by the expression of AOC3 and other associated markers.
    Proc Natl Acad Sci U S A. 2016;113:E2162-71.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: